INTERACTION BETWEEN ERBB- RECEPTORS AND HEREGULIN IN BREAST-CANCER TUMOR PROGRESSION AND DRUG-RESISTANCE

被引：58

作者：

LUPU, R

CARDILLO, M

HARRIS, L

HIJAZI, M

ROSENBERG, K

机构：

[1] Vincent T. Lombardi Cancer Res. Ctr., Georgetown Univ., School of Medicine and Lombardi Cancer Res. Center, Washington, DC 20007

来源：

SEMINARS IN CANCER BIOLOGY | 1995年 / 6卷 / 03期

关键词：

HEREGULIN; BREAST CANCER; GROWTH FACTOR RECEPTORS; ERBB; ONCOGENE;

D O I：

10.1006/scbi.1995.0016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The type 1 growth factor receptor family is increasingly recognized as important in the development and maintenance of breast cancer The family currently consists of four closely related members: the epidermal growth factor receptor (ECF-R/erbB-1), erbB-2, erbB-3 and erbB-4. Putative ligands which bind directly to or indirectly activate erbB-2/3/4 have been. characterized recently. This still growing family of EGF-related growth factors includes gp30, its homolog heregulin (HRG) the rat homolog neu differentiation factor (NDF) glial growth factors (GLIA) ARIA and a 50 kDa factor from COLO 16 cells. The understanding of the function, biology and interactions of these growth factor receptors and their ligands will have far-reaching implications for the prognosis and treatment of breast cancer This review focuses on. advances and future directions for further investigations intended to clarify the mechanism and significance of erbB/ligand interactions in breast cancer.

引用

页码：135 / 145

页数：11

共 143 条

[1] HER-2/NEU IN NODE-NEGATIVE BREAST-CANCER - PROGNOSTIC-SIGNIFICANCE OF OVEREXPRESSION INFLUENCED BY THE PRESENCE OF INSITU CARCINOMA [J].

ALLRED, DC ;

CLARK, GM ;

TANDON, AK ;

MOLINA, R ;

TORMEY, DC ;

OSBORNE, CK ;

GILCHRIST, KW ;

MANSOUR, EG ;

ABELOFF, M ;

EUDEY, L ;

MCGUIRE, WL .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :599-605

[2] OVEREXPRESSION OF HER-2 NEU AND ITS RELATIONSHIP WITH OTHER PROGNOSTIC FACTORS CHANGE DURING THE PROGRESSION OF INSITU TO INVASIVE BREAST-CANCER [J].

ALLRED, DC ;

CLARK, GM ;

MOLINA, R ;

TANDON, AK ;

SCHNITT, SJ ;

GILCHRIST, KW ;

OSBORNE, CK ;

TORMEY, DC ;

MCGUIRE, WL .

HUMAN PATHOLOGY, 1992, 23 (09) :974-979

[3] TAMOXIFEN UP-REGULATES C-ERBB-2 EXPRESSION IN ESTROGEN-RESPONSIVE BREAST-CANCER CELLS-INVITRO [J].

ANTONIOTTI, S ;

MAGGIORA, P ;

DATI, C ;

DEBORTOLI, M .

EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :318-321

[4]

ARTEAGA CL, 1994, CANCER RES, V54, P1

[5]

BACUS SS, 1993, CANCER RES, V53, P5251

[6]

BACUS SS, 1992, CANCER RES, V52, P2580

[7]

BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401

[8] ONCOGENIC ACTIVATION OF THE NEU-ENCODED RECEPTOR PROTEIN BY POINT MUTATION AND DELETION [J].

BARGMANN, CI ;

WEINBERG, RA .

EMBO JOURNAL, 1988, 7 (07) :2043-2052

[9] ESTROGEN-DEPENDENT, TAMOXIFEN-RESISTANT TUMORIGENIC GROWTH OF MCF-7 CELLS TRANSFECTED WITH HER2/NEU [J].

BENZ, CC ;

SCOTT, GK ;

SARUP, JC ;

JOHNSON, RM ;

TRIPATHY, D ;

CORONADO, E ;

SHEPARD, HM ;

OSBORNE, CK .

BREAST CANCER RESEARCH AND TREATMENT, 1992, 24 (02) :85-95

[10]

BERCHUCK A, 1990, CANCER RES, V50, P4087

← 1 2 3 4 5 6 7 8 9 10 →